Binnerstam/iStock via Getty Images A majority of members of an FDA advisory panel believe that the benefits of Novo Nordisk's ( NVO ) once weekly insulin icodec do not outweigh the risks. Seven of the 11 voting members of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting didn't agree that the benefits outweigh the risks, while four members did. Briefing documents provided by FDA scientists indicated concerns with hypoglycemia with insulin icodec in a key trial where it was compared to Novo's ( NVO ) once-daily Tresiba (insulin degludec).
Several panel members brought these concerns up. Novo Nordisk ( NVO ) did mention use of glucose monitoring devices in those prescribed the drug as one way to mitigate the hypoglycemia risk. Several members indicated that insulin icodec might be suitable for a subset of patients, though Novo would need to specify who they are.
Earlier this month, rival Eli Lilly ( LLY ) reported positive data from a pair of phase 3 trials for its weekly insulin, efsitora. More on Novo Nordisk Novo weight loss therapy cuts mortality risk in kidney disease SA Asks: Is Eli Lilly or Novo Nordisk a better investment? The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript.